Healthy PopulationNCT06473246
A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.
A study testing CBD Isolate (25 mg/0.5 ml), CBD Isolate (40 mg/0.5 ml) and CBD Isolate (50 mg/0.5 ml) in people with Healthy Population, run by Vedic Lifesciences Pvt. Ltd. at 6 sites in India.
Trial summary
The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique… Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Population
- What is being tested?
- CBD Isolate (25 mg/0.5 ml), CBD Isolate (40 mg/0.5 ml) and CBD Isolate (50 mg/0.5 ml)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 220 participants
- Where
- 6 sitesIndia
- Study dates
- 20 Feb 2025to 19 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male \& female individuals must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- Individuals who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Individual has a body weight of at least 50 kg (males) or 45 kg (females) and body mass index (BMI) within the range 18.5 to 29.9 kg/m2 (inclusive)
- Individuals with a stressed lifestyle as assessed by PSS scores within 27- 40.
- A male must agree to use contraception during the intervention period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period.
- A female is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
- Not a woman of childbearing potential (WOCBP)
- OR agrees to use the contraceptive during the intervention period and for at least 90 days after the last dose of study intervention
Who cannot join
- Individual has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinology related, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention, or interfering with the interpretation of data.
- Males who has a history of oligospermia, vasectomy and other sperm abnormalities.
- Females who have irregularity or problems in menstrual cycles or diagnosed with polycystic ovarian syndrome.
- Individuals with Type 1 and Type 2 Diabetes mellitus and on medication.
- Individuals with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg.
- Individuals on anti-hypertensives.
Show all 21Show fewer
- History and/or current cases of chronic alcohol consumption or heavy drinkers as defined by:
- For men, consuming more than 4 drinks on any day or more than 14 drinks/week
- For women, consuming more than 3 drinks on any day or more than 7 drinks/week
- Peri and post-menopausal women with no menstrual cycle in the last 6 months
- Individuals with a history or actively under the influence of Hemp or CBD products by any means of administration
- Individual has a known hypersensitivity to any components of the study medication or comparative drugs (and/or an investigational device) as stated in this protocol
- Individual has a history of unexplained syncope or a family history of sudden death due to long QT syndrome
- Individual with a history and/or currently diagnosed of cancer like lymphoma, leukaemia, or any malignancy.
- Individual has past or intended use of prohibited medication or prescription medication including herbal medications within 2 weeks or 5 half-lives prior to dosing
- Individuals have taken sleep medication within 2 weeks prior to screening
- Individual has used hepatic enzyme-inducing drugs within 2 months prior to dosing
- Individuals has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.5 times upper limit of normal (ULN)
- Individual has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- Individual has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline
- Individual has a history of human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
India6 sites
Shivam Hospital
Dombivali, Maharashtra, 421203
Dhanwantri Hospital
Pune, Maharashtra, 411011
Vedant Multispeciality Hospital
Pune, Maharashtra, 411019
Punawale Hospital
Pune, Maharashtra, 411033
Vishwaraj Hospital
Pune, Maharashtra, 412201
Shree Ashirwad Hospital
Thane, Maharashtra, 421201
About this study
Official title: A Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.
The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique randomization code. Each group will have at least 30 participants (total 150 completers) after accounting for a dropout/withdrawal rate of 25%. The intervention duration for all the study participants is 180 days.
- Conditions
- Healthy Population
- Being tested
- CBD Isolate (25 mg/0.5 ml), CBD Isolate (40 mg/0.5 ml), CBD Isolate (50 mg/0.5 ml), CBD Broad Extract (50 mg/0.5 ml), Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBD Isolate (25 mg/0.5 ml)Dietary supplement
0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
CBD Isolate (40 mg/0.5 ml)Dietary supplement
0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
CBD Isolate (50 mg/0.5 ml)Dietary supplement
0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
CBD Broad Extract (50 mg/0.5 ml)Dietary supplement
0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
PlaceboDietary supplement
0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
| Study group | Role | What they receive |
|---|---|---|
| CBD Isolate (25 mg/0.5 ml) | Active comparator | 0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. Receives: Dietary Supplement: CBD Isolate (25 mg/0.5 ml) |
| CBD Isolate (40 mg/0.5 ml) | Active comparator | 0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. Receives: Dietary Supplement: CBD Isolate (40 mg/0.5 ml) |
| CBD Isolate (50 mg/0.5 ml) | Active comparator | 0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. Receives: Dietary Supplement: CBD Isolate (50 mg/0.5 ml) |
| CBD Broad Extract (50 mg/0.5 ml) | Active comparator | 0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. Receives: Dietary Supplement: CBD Broad Extract (50 mg/0.5 ml) |
| Placebo | Placebo comparator | 0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Fasting Glucose normal range is 74 - 106 mg/dL
Measured: Day -5 to Day -1
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Fasting Glucose normal range is 74 - 106 mg/dL
Measured: Day 90
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Fasting Glucose normal range is 74 - 106 mg/dL
Measured: Day 180
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen, Blood Urea and Calcium tests.
Normal range for these tests are mentioned below:
Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL
GFR:
Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
Measured: Day -5 to Day -1
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen, Blood Urea and Calcium tests.
Normal range for these tests are mentioned below:
Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL
GFR:
Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
Measured: Day 90
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Estimated Glomerular Filtration Rate (eGFR), Blood Urea Nitrogen, Blood Urea and Calcium tests.
Normal range for these tests are mentioned below:
Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL eGFR: 60 - 200 mL/min/1.73 m² Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
Measured: Day 180
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood.
Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
Measured: Day -5 to -1
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood.
Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
Measured: Day 90
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood.
Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
Measured: Day 180
Secondary outcomes (18)
To assess the safety and tolerability of VL-SE-01 using blood, which includes Complete Blood Count (CBC).
CBC measures red blood cells (RBC) which basically carries oxygen, white blood cells (WBC)(Leukocytes), which fights with infection, hemoglobin (Hb), which carries oxygen protein in blood cells, and platelets, which help blood to clot. A complete blood count can show unusual increases or decreases in cell counts.
Normal ranges for the parameters are as follows:
Hb: Males: 13 - 17 g/dL; Females - 11.5 - 15.2 g/dL Total RBC: Males - 4.2 - 6.0 million cells/cumm; Females - 3.8 - 5.2 million cells/cumm Total WBC: 3500 - 10000 / cumm Platelet Count: 150000 - 400000 / cumm
Measured: Day -5 to Day -1, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Inflammation by analyzing CRP levels.
Normal reference range: 0 -5.0 mg/L
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Hormonal profile (Luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol and progesterone)
Leutinizing Hormone in Females reference range:
Follicular Phase : 2.4 - 12.6 mIU/mL Ovulating Phase : 14.0 - 95.6 mIU/mL Luteal Phase : 1.0 - 11.4 mIU/mL Post menopausal : 7.7 - 58.5 mIU/mL
Follicular Stimulating Hormones in Females reference range:
Follicular Phase : 3.5 - 12.5 mIU/mL Ovulating Phase : 4.7 - 21.5 mIU/mL Luteal Phase : 1.7 - 7.7 mIU/mL Post menopausal : 25.8 - 134.8 mIU/mL
Progesterone in Females reference ranges:
Follicular phase: 0.2 - 1.5 ng/ml Ovulatory phase: 0.8 - 3.0 ng/ml Luteal phase: 1.7 - 27.0 ng/ml Post menopause: 0.1 - 0.8 ng/ml
Estradiol in females reference range:
Follicular phase :12.5-166 pg/ml Ovulatory phase :85.5-498 pg/ml Luteal phase : 43.8-211 pg/ml Post menopause : 5.0-54.7 pg/ml Pregnancy,1st trimester: 215-4300 pg/ml
Testosterone in Males reference range: 2.8 - 8.0 ng/mL
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Thyroid profile (T3, T4, TSH)
Total Triiodothyronine (T3) reference range: 1.3 - 3.1 nmol/L Total Thyroxine (T4) reference range: 5.1 - 14.1 μg/dL Thyroid Stimulating Hormone (TSH) reference range: 0.27 - 4.2 μIU/mL
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Lipid Profile as assessed by levels of total cholesterol, LDL, HDL and triglycerides
Total Cholesterol: Desirable: < 200 mg/dL, Borderline High : 200 - 239 mg/dL, High : ≥ 240 mg/dL Triglyceride: Normal : < 150 mg/dL, Borderline : 151 - 199 mg/dL, High : 200 - 499 mg/dL, Very High : > 500 mg/dL HDL Cholesterol: 40 - 60 mg/dL LDL Cholesterol: Optimal : < 100 mg/dL, Near / Above Optimal : 101-129 mg/dL, Borderline High : 130 - 159 mg/dL, High : 160 -189 mg/dL, Very High : > 190 mg/dL
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 on Semen.
Assessment of semen will be done using the following parameters:
Physical examination which includes factors like Volume (>1.5 ml), appearance, Colour, Viscosity (<2 cm thread after liquefaction) and pH (>= 7.2) of the sample.
Microscopic Examination which includes Sperm count [Sperm concentration is the number of sperm per milliliter of semen (Reference Range: >=16 Million/ml)] and Motility [Sperm motility is the ability of your sperm to swim (>=42 %)]
Measured: Day -5 to Day -1 and Day 180
To assess the safety and tolerability of VL-SE-01 using blood Plasma levels of CBD and its metabolites [7-Carboxy-cannabidiol (7-COOH-CBD) and 7-Hydroxy-cannabidiol (7-OH-CBD)]
(will be conducted in 15 participants only in each group except placebo)
Measured: Day 195 (single timepoint)
To assess the safety and tolerability of VL-SE-01 on Blood Pressure.
Vitals signs measures basic functions of the body. In this case, Blood pressure (BP) will be measured.
Blood pressure will be measured using a calibrated digital monitor.
Systolic BP (measured in mmHg): Optimal - <120, Normal - 120 - 129, High normal - 130 - 139, Grade 1 hypertension - 140 - 159, Grade 2 hypertension - 160 - 179, Grade 3 hypertension - ≥180, Isolated systolic hypertension - ≥140.
Diastolic BP (measured in mmHg): Optimal - <80, Normal - 80 - 84, High normal - 85 - 89, Grade 1 hypertension - 90 - 99, Grade 2 hypertension - 100 - 109, Grade 3 hypertension - ≥110, Isolated systolic hypertension - < 90.
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 on Pulse Rate.
Vitals signs measures basic functions of the body. In this case Heart rate [also known as Pulse rate (PR)] will be measured.
Pulse rate will be measured by palpatory method by counting the number of beats in 30 seconds.
Normal Pulse rate: 60 - 100 beats per minute (bpm) Bradycardia: < 60 bpm Tachycardia: > 100 bpm
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using Electrocardiogram.
The electrocardiograph is a device that picks up electrical activity originating in the heart from the surface of the body for clinical diagnosis of cardiac function. The following parameters will be considered for the study:
The QT interval is the time from the beginning of the QRS complex, representing ventricular depolarization, to the end of the T wave, resulting from ventricular repolarization. In general, the normal QT interval is below 400 to 440 milliseconds (ms), or 0.4 to 0.44 seconds. Women have a longer QT interval than men.
The corrected QT interval (QTc) estimates the QT interval at a standard heart rate of 60 bpm. Normal values for the QTc range from 350 to 450 ms for adult men and from 360 to 460 ms for adult women; however, 10%-20% of otherwise healthy persons may have QTc values outside this range.
The PR interval is the time from the beginning of the P wave (atrial depolarization) to the beginning of the QRS complex (ventricular depolarization). The normal
Measured: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using Treatment emergent Adverse Events (TEAEs).
The number and percent of research participants reporting AEs will be tabulated by intervention group and will be compared between the groups.
Measured: Day 0, Day 90, Day 180 and Day 195
To evaluate the efficacy of VL-SE-01 on the basis of Incidence of gastrointestinal dysfunction using Structured Assessment of Gastrointestinal Symptoms (SAGIS) questionnaire.
SAGIS is a suitable questionnaire to assess gastrointestinal complaints like Decreased appetite, Diarrhea, Weight decreased, Gastroenteritis Abdominal pain, discomfort etc.
It consists of 22 items as well as two open questions asking for the participant's most and second most important clinical problem. Q1 to Q22 are summed together to give a total symptom burden score. The total symptoms burden score can range from 0 to 88.The number of items between Q1 and Q22 that are scored severe (3) or very severe (4) are added together. The global impact score can range from 0 to 22.
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Sleep quality using the PSQI questionnaire
The questions relate to a person's usual sleep habits during the past month. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). All the seven component scores are to be added together for calculating the Global PSQI Score. Higher scores indicate worse sleep quality.
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Insomnia using Insomnia Severity Index (ISI)
The questionnaire evaluates the sleep quality in last two weeks. The seven answers are added up to the total score.The scores of 0-7 determines no clinically significant insomnia, 8-14 determines sub threshold insomnia, 15-21 has moderate severity which determines clinical insomnia and lastly 22-28 has severe insomnia.
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Fatigue will be assessed using fatigue severity scale (FSS)
The FSS is a self-administered questionnaire with 9 items (questions) investigating the severity of fatigue in different situations during the past week. Grading of each item ranges from 1 to 7, where 1 indicates strong disagreement and 7 indicates strong agreement, and the final score represents the mean value of the 9 items.
A visual analogue scale is also included with the scale in which the respondents will be asked to denote the severity of their fatigue at the present moment by placing a mark on a line extending from "no fatigue" to "fatigue as bad as could be." Higher scores on the scale are indicative of more severe fatigue
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Stress response as assessed by Perceived Stress Scale (PSS).
The questions in this scale ask about feelings and thoughts of an individual during the last month.
Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Menstrual cycle regularity.
A diary will be provided to the participant to record their monthly menstruation period start date and stop date. The average length of a menstrual cycle is of 28 days, however it varies for every female.
Measured: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Plasma levels of CBD and its metabolites [7-Carboxy-cannabidiol (7-COOH-CBD) and 7-Hydroxy-cannabidiol (7-OH-CBD)]
This will be conducted in 15 participants only in each group except placebo.
Measured: 0 hour, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours at Day 0, Day 90, Day 180
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2024
- Study start20 Feb 2025
- Primary completion19 Jun 2026
- Study completion19 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy PopulationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, Double-Blind and Placebo controlled
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 220 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vedic Lifesciences Pvt. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06473246
- Sponsor's protocol ID
- SE/230302/CBD/SS
- Status last verified
- Sep 2026
- First submitted
- 3 Jun 2024
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.
- ClinicalTrials.gov ID
- NCT06473246
- Acronym / sponsor ID
- SE/230302/CBD/SS
- Conditions
- Healthy Population
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 220 participants (actual)
- Lead sponsor
- Vedic Lifesciences Pvt. Ltd.Industry (pharma, biotech, devices)
- Study start
- 20 Feb 2025 (actual)
- Primary completion
- 19 Jun 2026 (actual)
- Study completion
- 19 Jun 2026 (actual)
- First posted
- 25 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique randomization code. Each group will have at least 30 participants (total 150 completers) after accounting for a dropout/withdrawal rate of 25%. The intervention duration for all the study participants is 180 days.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
- Model description
- Randomized, Double-Blind and Placebo controlled
| Arm | Type | Receives |
|---|---|---|
| CBD Isolate (25 mg/0.5 ml) | Active comparator | Dietary Supplement: CBD Isolate (25 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. |
| CBD Isolate (40 mg/0.5 ml) | Active comparator | Dietary Supplement: CBD Isolate (40 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. |
| CBD Isolate (50 mg/0.5 ml) | Active comparator | Dietary Supplement: CBD Isolate (50 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. |
| CBD Broad Extract (50 mg/0.5 ml) | Active comparator | Dietary Supplement: CBD Broad Extract (50 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. |
| Placebo | Placebo comparator | Dietary Supplement: Placebo0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Male \& female individuals must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- Individuals who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Individual has a body weight of at least 50 kg (males) or 45 kg (females) and body mass index (BMI) within the range 18.5 to 29.9 kg/m2 (inclusive)
- Individuals with a stressed lifestyle as assessed by PSS scores within 27- 40.
- A male must agree to use contraception during the intervention period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period.
Key exclusion criteria (21 listed)
- Individual has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinology related, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention, or interfering with the interpretation of data.
- Males who has a history of oligospermia, vasectomy and other sperm abnormalities.
- Females who have irregularity or problems in menstrual cycles or diagnosed with polycystic ovarian syndrome.
- Individuals with Type 1 and Type 2 Diabetes mellitus and on medication.
- Individuals with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBD Isolate (25 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. | Dietary supplement | CBD Isolate (25 mg/0.5 ml) |
| CBD Isolate (40 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. | Dietary supplement | CBD Isolate (40 mg/0.5 ml) |
| CBD Isolate (50 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. | Dietary supplement | CBD Isolate (50 mg/0.5 ml) |
| CBD Broad Extract (50 mg/0.5 ml)0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. | Dietary supplement | CBD Broad Extract (50 mg/0.5 ml) |
| Placebo0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed. | Dietary supplement | Placebo |
Primary outcome
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day -5 to Day -1
Fasting Glucose normal range is 74 - 106 mg/dL
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 90
Fasting Glucose normal range is 74 - 106 mg/dL
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 180
Fasting Glucose normal range is 74 - 106 mg/dL
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day -5 to Day -1
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen, Blood Urea and Calcium tests. Normal range for these tests are mentioned below: Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL GFR: Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 90
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen, Blood Urea and Calcium tests. Normal range for these tests are mentioned below: Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL GFR: Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 180
Renal function tests measure the efficiency of kidneys and include Electrolytes (Sodium, Potassium, and Chloride), Creatinine, Estimated Glomerular Filtration Rate (eGFR), Blood Urea Nitrogen, Blood Urea and Calcium tests. Normal range for these tests are mentioned below: Sodium:136 - 145 mmol/L Potassium: 3.5 - 5.1 mmol/L Chloride: 98 - 107 mmol/L Creatinine: Males - 0.7 - 1.2 mg/dL; Females - 0.5 - 0.9 mg/dL eGFR: 60 - 200 mL/min/1.73 m² Blood Urea Nitrogen: Males - 18 yrs - 49 yrs : 8.87-22.88 mg/dL, > 50 yrs : 9.80-22.88 mg/dL; Females - 18 yrs - 49 yrs : 7.47-17.74 mg/dL, > 50 yrs : 8.87-21.94 mg/dL Blood Urea: Males - 18 yrs - 49 yrs : 19 - 49 mg/dL, > 50 yrs : 21 - 49 mg/dL; Females - 18 yrs - 49 yrs : 16 - 38 mg/dL, > 50 yrs : 19 - 47 mg/dL Calcium: 8.6 - 10.0 mg/dL
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day -5 to -1
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood. Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 90
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood. Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption.
Time frame: Day 180
Liver Function tests help determine the health of liver by measuring the levels of Albumin, Total Proteins, Alkaline Phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Bilirubin, and gamma-glutamyl transferase (GGT) levels in blood. Albumin: 3.5 - 5.2 g/dL Total Proteins: 6.6 - 8.9 g/dL Alkaline Phosphatase: Males - 40 - 129 U/L; Females - 35 - 104 U/L ALT: Males - Up to 41 U/L; Females - Up to 33 U/L AST: Males - Up to 40 U/L; Females - Up to 32 U/L Bilirubin: Total Bilirubin - Up to 1.2 mg/dL; Direct Bilirubin - Up to 0.3 mg/dL; Indirect Bilirubin - Up to 0.9 mg/dL GGT: Males - 10 - 71 U/L; Females - 6 - 42 U/L
18 secondary outcomes
To assess the safety and tolerability of VL-SE-01 using blood, which includes Complete Blood Count (CBC).
Time frame: Day -5 to Day -1, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Inflammation by analyzing CRP levels.
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Hormonal profile (Luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol and progesterone)
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Thyroid profile (T3, T4, TSH)
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using blood, which includes Lipid Profile as assessed by levels of total cholesterol, LDL, HDL and triglycerides
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 on Semen.
Time frame: Day -5 to Day -1 and Day 180
To assess the safety and tolerability of VL-SE-01 using blood Plasma levels of CBD and its metabolites [7-Carboxy-cannabidiol (7-COOH-CBD) and 7-Hydroxy-cannabidiol (7-OH-CBD)]
Time frame: Day 195 (single timepoint)
To assess the safety and tolerability of VL-SE-01 on Blood Pressure.
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 on Pulse Rate.
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using Electrocardiogram.
Time frame: Day 0, Day 90, Day 180 and Day 195
To assess the safety and tolerability of VL-SE-01 using Treatment emergent Adverse Events (TEAEs).
Time frame: Day 0, Day 90, Day 180 and Day 195
To evaluate the efficacy of VL-SE-01 on the basis of Incidence of gastrointestinal dysfunction using Structured Assessment of Gastrointestinal Symptoms (SAGIS) questionnaire.
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Sleep quality using the PSQI questionnaire
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Insomnia using Insomnia Severity Index (ISI)
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Fatigue will be assessed using fatigue severity scale (FSS)
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Stress response as assessed by Perceived Stress Scale (PSS).
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Menstrual cycle regularity.
Time frame: Day 0, Day 90, and Day 180
To evaluate the efficacy of VL-SE-01 on the basis of Plasma levels of CBD and its metabolites [7-Carboxy-cannabidiol (7-COOH-CBD) and 7-Hydroxy-cannabidiol (7-OH-CBD)]
Time frame: 0 hour, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours at Day 0, Day 90, Day 180
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Population
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Not yet recruitingPhase 1
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)
Healthy, Renal Impairment
RecruitingPhase 1
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Overweight and/or Obesity, Healthy Participants
Recruiting
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations
Recruiting
Nutrition Outcomes Using a Randomized Intervention Via Smartphone on Dietary Habits
Healthy Adult Participants, Mindful Eating Intervention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CBD Isolate (25 mg/0.5 ml), CBD Isolate (40 mg/0.5 ml) and CBD Isolate (50 mg/0.5 ml) in people with Healthy Population, run by Vedic Lifesciences Pvt. Ltd. at 6 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption. (time frame: Day -5 to Day -1). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.